ELDN Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29, 2022 at 2:00 p.m. ET in New York City.

To register in advance for the fireside chat webcast, sign up .

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at .

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at .

Follow Eledon Pharmaceuticals on social media: ;

Investor Contact:

Stephen Jasper

Gilmartin Group

(858) 525-2047



EN
22/09/2022

Underlying

ELDNEledon Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eledon Pharmaceuticals Inc

 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Finan...

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney transplantation in November 2025 Cash, cash equivalents and short-term investments of $107.6 million as of June 30, 2025 IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its second quarter 2025...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Te...

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegoprubart may improve 5-year graft survival vs. current standard of care Tegoprubart continues to be well tolerated with no cases of death, graft loss, drug related tremor, or new-onset diabetes Conference call to be ...

August 6, 2025 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Da...

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025 IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplanta...

July 30, 2025 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Te...

Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025 IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation will be presented at the World Transplant Congress (WTC) taking place in San Francisco from August 2-6, 2025. The oral pres...

July 17, 2025 1 EN
 PRESS RELEASE
Free
ELDN Eledon Pharmace...

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York Cit...

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginning at 8:30 am ET. The event will feature members of Eledon’s executive team and the following leading experts in transplantation: Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minne...

June 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch